A detailed history of Two Sigma Investments, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 154,030 shares of PHAT stock, worth $1.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
154,030
Previous 303,431 49.24%
Holding current value
$1.4 Million
Previous $3.13 Million 10.91%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.25 - $19.5 $1.53 Million - $2.91 Million
-149,401 Reduced 49.24%
154,030 $2.78 Million
Q2 2024

Aug 14, 2024

SELL
$8.97 - $12.05 $1.47 Million - $1.98 Million
-164,017 Reduced 35.09%
303,431 $3.13 Million
Q1 2024

May 15, 2024

BUY
$6.21 - $11.05 $1.25 Million - $2.22 Million
200,591 Added 75.17%
467,448 $4.96 Million
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $1.28 Million - $1.96 Million
182,794 Added 217.45%
266,857 $2.44 Million
Q3 2023

Nov 14, 2023

BUY
$10.26 - $15.7 $436,696 - $668,239
42,563 Added 102.56%
84,063 $871,000
Q2 2023

Aug 14, 2023

BUY
$7.28 - $14.32 $90,272 - $177,568
12,400 Added 42.61%
41,500 $594,000
Q1 2023

May 15, 2023

BUY
$6.19 - $12.36 $180,129 - $359,676
29,100 New
29,100 $207,000
Q2 2022

Aug 15, 2022

SELL
$6.2 - $15.5 $30,454 - $76,136
-4,912 Reduced 12.21%
35,304 $298,000
Q1 2022

May 16, 2022

SELL
$11.55 - $20.06 $272,349 - $473,014
-23,580 Reduced 36.96%
40,216 $547,000
Q4 2021

Feb 14, 2022

BUY
$17.83 - $33.15 $735,327 - $1.37 Million
41,241 Added 182.85%
63,796 $1.26 Million
Q3 2021

Nov 15, 2021

SELL
$30.69 - $36.83 $534,896 - $641,910
-17,429 Reduced 43.59%
22,555 $724,000
Q2 2021

Aug 16, 2021

SELL
$32.66 - $39.87 $479,154 - $584,932
-14,671 Reduced 26.84%
39,984 $1.35 Million
Q1 2021

May 17, 2021

BUY
$33.86 - $48.68 $1.85 Million - $2.66 Million
54,655 New
54,655 $2.05 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $356M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.